Free Trial

Pharvaris (PHVS) Competitors

Pharvaris logo
$21.66 +0.70 (+3.34%)
As of 03:42 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

PHVS vs. ACLX, KYMR, PTGX, CRNX, ZLAB, AKRO, ACAD, AAPG, MIRM, and LNTH

Should you be buying Pharvaris stock or one of its competitors? The main competitors of Pharvaris include Arcellx (ACLX), Kymera Therapeutics (KYMR), Protagonist Therapeutics (PTGX), Crinetics Pharmaceuticals (CRNX), Zai Lab (ZLAB), Akero Therapeutics (AKRO), ACADIA Pharmaceuticals (ACAD), Ascentage Pharma Group International (AAPG), Mirum Pharmaceuticals (MIRM), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry.

Pharvaris vs. Its Competitors

Arcellx (NASDAQ:ACLX) and Pharvaris (NASDAQ:PHVS) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.

Arcellx has a beta of 0.31, meaning that its share price is 69% less volatile than the S&P 500. Comparatively, Pharvaris has a beta of -2.77, meaning that its share price is 377% less volatile than the S&P 500.

Arcellx currently has a consensus target price of $112.69, indicating a potential upside of 22.94%. Pharvaris has a consensus target price of $37.17, indicating a potential upside of 71.59%. Given Pharvaris' higher possible upside, analysts plainly believe Pharvaris is more favorable than Arcellx.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arcellx
1 Sell rating(s)
1 Hold rating(s)
12 Buy rating(s)
1 Strong Buy rating(s)
2.87
Pharvaris
1 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.50

Arcellx has higher revenue and earnings than Pharvaris. Arcellx is trading at a lower price-to-earnings ratio than Pharvaris, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arcellx$56.98M89.22-$107.35M-$3.42-26.80
PharvarisN/AN/A-$145.24M-$3.36-6.45

96.0% of Arcellx shares are owned by institutional investors. 8.4% of Arcellx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Pharvaris had 2 more articles in the media than Arcellx. MarketBeat recorded 12 mentions for Pharvaris and 10 mentions for Arcellx. Pharvaris' average media sentiment score of 0.78 beat Arcellx's score of 0.04 indicating that Pharvaris is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Arcellx
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Pharvaris
3 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Pharvaris has a net margin of 0.00% compared to Arcellx's net margin of -329.93%. Arcellx's return on equity of -43.04% beat Pharvaris' return on equity.

Company Net Margins Return on Equity Return on Assets
Arcellx-329.93% -43.04% -27.41%
Pharvaris N/A -69.09%-63.34%

Summary

Arcellx beats Pharvaris on 10 of the 16 factors compared between the two stocks.

Get Pharvaris News Delivered to You Automatically

Sign up to receive the latest news and ratings for PHVS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PHVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PHVS vs. The Competition

MetricPharvarisMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.13B$3.40B$6.05B$10.51B
Dividend YieldN/A2.30%5.73%4.80%
P/E Ratio-6.4523.0384.9327.30
Price / SalesN/A268.08515.79197.96
Price / CashN/A46.9537.5761.53
Price / Book3.9110.5412.426.82
Net Income-$145.24M-$52.58M$3.32B$276.59M
7 Day Performance-5.74%0.59%0.53%0.00%
1 Month Performance-7.36%15.50%10.24%7.96%
1 Year Performance4.03%18.01%75.92%35.10%

Pharvaris Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PHVS
Pharvaris
2.7474 of 5 stars
$21.66
+3.3%
$37.17
+71.6%
+1.9%$1.13BN/A-6.4530News Coverage
Analyst Forecast
Gap Up
High Trading Volume
ACLX
Arcellx
2.0028 of 5 stars
$84.38
-0.8%
$114.31
+35.5%
+0.6%$4.72B$107.94M-24.6780Analyst Revision
KYMR
Kymera Therapeutics
1.344 of 5 stars
$57.55
-0.6%
$61.26
+6.5%
+26.5%$4.14B$47.07M-16.58170Insider Trade
PTGX
Protagonist Therapeutics
1.6843 of 5 stars
$64.14
-1.1%
$68.36
+6.6%
+66.0%$4.03B$209.18M91.63120Analyst Forecast
Insider Trade
Gap Down
CRNX
Crinetics Pharmaceuticals
3.7504 of 5 stars
$41.68
+2.0%
$74.45
+78.6%
-17.0%$3.85B$1.04M-10.14210
ZLAB
Zai Lab
2.7795 of 5 stars
$33.31
-1.3%
$56.35
+69.2%
+18.9%$3.77B$398.99M-16.331,869News Coverage
Positive News
AKRO
Akero Therapeutics
3.6892 of 5 stars
$46.04
-0.1%
$81.14
+76.2%
+79.3%$3.69BN/A-23.0230Insider Trade
ACAD
ACADIA Pharmaceuticals
4.5116 of 5 stars
$21.59
-1.0%
$29.12
+34.9%
+35.8%$3.68B$1.02B16.23510Analyst Forecast
AAPG
Ascentage Pharma Group International
N/A$39.86
+1.2%
N/AN/A$3.67B$134.35M0.00600News Coverage
Gap Up
MIRM
Mirum Pharmaceuticals
3.172 of 5 stars
$72.53
-0.6%
$76.50
+5.5%
+84.3%$3.66B$336.89M-59.94140Positive News
LNTH
Lantheus
4.5688 of 5 stars
$52.70
-2.1%
$85.50
+62.2%
-50.3%$3.66B$1.53B14.02700Analyst Revision

Related Companies and Tools


This page (NASDAQ:PHVS) was last updated on 10/15/2025 by MarketBeat.com Staff
From Our Partners